119th Congress · introduced in the Senate · Jan 23, 2025
DTC Act of 2025
Official title from Congress.gov
Latest action (Jan 23, 2025): Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in Senate (Jan 23, 2025)
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025
This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.
Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.
The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.
Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
Introduced in Senate
Actions from Congress.gov, newest first.
Administrative law and regulatory procedures · Civil actions and liability · Department of Health and Human Services · Health care costs and insurance · Marketing and advertising · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
32 citations; showing the 25 most recently posted.
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$3,010,000
Spent on own lobbying
…DeGette, Diana - Copay caps H.R. 10369 - Net Effective Cost Transparency and Prescription Drug Affordability Act - Rep. Mackenzie, Ryan - Requirements for PBMs S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$90,000
Paid to lobbying firm
Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 2, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 22, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Pharmacy
$3,010,000
Spent on own lobbying
…ducts H.R. 7837 - Most Favored Patient Act - Rep. Meuser, Daniel - MFN demonstration H.R. 8779 - PBM Act - Rep. Harshbarger, Diana - PBM ownership requirements S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$90,000
Paid to lobbying firm
Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act of 2025..
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 6, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted May 4, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$5,320,000
Spent on own lobbying
…Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products H.R. 7837 - Most Favored Patient Act - Rep. Meuser, Daniel - MFN demonstration S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Medicare/Medicaid
$90,000
Paid to lobbying firm
Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act of 2025..
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Pharmacy
$4,120,000
Spent on own lobbying
…, Nicole - Medicare cost-sharing limit for drugs H.R. 6255 - Affordable Insulin Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 16, 2026 · issue area: Medicare/Medicaid
$90,000
Paid to lobbying firm
Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 6, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Pharmacy
$4,230,000
Spent on own lobbying
…Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025. Issues related to H.R. 1, One Big Beautiful Bill Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · lobbying firm or registrant: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medicare/Medicaid
$2,948,162
Spent on own lobbying
…iors Access to Critical Medications Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4317; PBM Reform Act H.R. 4623; Plain Prescription Prices Act S.229/H.R.3789, the Drug Price Transparency for Consumers Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · lobbying firm or registrant: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$2,948,162
Spent on own lobbying
S. 1041; Affordable Prescriptions for Patients Act S. 1040; Drug Competition Enhancement Act H.R. 3798/ S. 229; Drug-price Transparency for Consumers Act S. 1414; Expedited Access to Biosimilars Act S. 2099; Restore Prescription Drug Discount Act H.R. 5371; Continuing A…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Medicare/Medicaid
$90,000
Paid to lobbying firm
Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act. H.R. 1/PL 119-21 - One Big Beautiful Bill Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AARP · lobbying firm or registrant: AARP
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · amended · posted Oct 9, 2025 · issue area: Pharmacy
$6,630,000
Spent on own lobbying
…cussed pharmacy benefit managers. S. 527, Prescription Pricing for the People Act of 2025. S. 526, the Pharmacy Benefit Manager (PBM) Transparency Act of 2025. S. 229, the Drug-Price Transparency for Consumers (DTC) Act of 2025. No bill number. Discussed Medicare Part D. No bill number. Discussed cap on out-of-pocket prescri…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Sep 18, 2025 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Aug 5, 2025 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 22, 2025 · issue area: Pharmacy
$4,050,000
Spent on own lobbying
…drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirem…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 22, 2025 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to prescription drug prices. S.1041 Affordable Prescriptions for Patients Act. Fair Accountability and Innovative Research Drug Pricing Act. S.229 Drug Price Transparency for Consumers Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing